Document:

Exhibit 10.35

 

Certain identified information has been excluded from the exhibit pursuant to Item 601(a)(6) of Regulation
S-K due to personal privacy concerns or pursuant to Item 601(b)(10)(iv) because it is both not material and is the type of information
that the registrant treats as private or confidential. Redacted information is indicated by: [***]

 

THIS ASSIGNMENT is made the 18th
day of February, 2005 between NEIL R. CASHMAN ("Cashman") and MARTY LEHTO ("Lehto")
(together the "Assignors") and THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO ("University")
and AMORFIX LIFE SCIENCES LTD (the "Assignee"), a corporation incorporated under the laws of Canada (collectively
the "Parties").

 

WHEREAS the Assignors have invented an
epitope protection technology, and have filed a PCT application entitled "Epitope Protection Assay" on August 20, 2004 to the
Canadian Receiving Office (the "Patent Application") attached as Schedule A;

 

WHEREAS, Cashman disclosed the technology
to the University on October 30, 2002 by way of an invention disclosure form attached as Schedule B (the "Invention Disclosure");

 

WHEREAS Cashman assigned all rights, title
and interest in the epitope protection technology to the University on September 3, 2003 which agreement is attached as Schedule C. The
University assigned all rights, title and interest in the epitope protection technology back to Cashman on September 19, 2003 (the "University
Assignment") which agreement is attached as Schedule D, subject to certain terms and conditions including but not limited to a [***]
percent ([***]%) revenue share (the "Revenue Interest") and a non-exclusive licence to use the Invention solely for research,
administration and academic purposes (collectively, the "Rights of the University");

 

WHEREAS the Invention Disclosure was subsequently
amended on September 21, 2004 which agreement is attached as Schedule E, to include Lehto as an inventor and the University Assignment
was amended accordingly;

 

WHEREAS, subject to the Rights of the University,
the Assignors have the right -to assign and transfer all rights, title and interest in the Invention to the Assignee;

 

WHEREAS the Assignee will have [***] ([***])
common shares ("Founder shares") issued and outstanding at an issue price of $0.00001 per Founder share following the issuance
of Founder shares pursuant to clause 3.1.1, of which Cashman and Lehto are the beneficial owners of [***] Founder shares and [***] Founder
shares, respectively;

 

WHEREAS the Assignee intends to complete
a reverse take-over with a corporation ("pubco") listed on the TSX Venture Exchange, pursuant to which the Assignee would either
become a wholly-owned subsidiary of the pubco or amalgamate with the pubco;

 

AND WHEREAS, the Assignee, the full post
office address of whose registered office is Suite 1400, 1055 West Hastings Street, Vancouver, British Columbia, V6E 2E9, is desirous
of acquiring the entire right, title and interest in and to the technology and the associated patents.

 

NOW THEREFORE THE PARTIES HERETO AGREE AS FOLLOWS;

 

		1.	DEFINITIONS

 

		1.1	"Invention" means the epitope protection technology as described in the Invention Disclosure
as revised including any Patent Rights and Know-How.

 

		1.2	"Improvements" means any and all improvements, variations, updates, modifications or enhancements
to the Invention created by either one or both of the Assignors that are within the scope of the claims of the
Patent Rights which have been created under any Research Agreement with the University.

 

     

     

    

 

		1.3	"Know-How" means any and all trade secrets, proprietary know-how, confidential information,
materials, research data and protocols directly and exclusively related to the Patent Rights.

 

		1.4	"Patent Rights" means the Patent Application, including any patents issuing therefrom and any
further applications claiming priority from this application, as well as any continuations, divisionals thereof, or any substitute application
therefore or equivalent thereof, and any patent issuing thereon, including any re-issues, renewals, extensions, or re-examinations thereof,
and any confirmation patent or registration patent, or patent of additions based on any such patent of the above in all jurisdictions
of the world.

 

		1.5	"Research Agreement" means any agreement between the University and Assignee, in the standard
form and which includes a right of first refusal to obtain the rights to commercially exploit intellectual property developed under the
agreement on terms (including compensation to the University) that generally reflect the industry norm.

 

		2.	ASSIGNMENTS

 

		2.1	Subject to the terms and conditions set out below, the Assignors for themselves and for their successors
and assigns, hereby sell, assign and transfer to the Assignee all right, title, interest and obligations which they now have, or may hereafter
have, in the Invention, as assigned to them under the University Assignment.

 

		2.2	The Assignors agree to execute any applications, transfers, assignments and/or such other documents the
Assignee may consider necessary or desirable from time to time for the purpose of obtaining, maintaining or vesting in and/or assigning
to Assignee absolute title to any patents, copyright, integrated circuit topography, industrial design or trade mark registrations for
the Invention; or for the purpose of applying for, prosecuting, obtaining or protecting any such patents, copyright, integrated circuit
topography, industrial design or trade mark registrations in any and all parts of the world and Assignors further agree to cooperate and
assist in every way possible in the prosecution and protection of any such applications and the rights granted in respect thereof.

 

		3.	CONSIDERATION

 

		3.1	In consideration for this sale, assignment and transfer of the Invention, the Assignee shall:

 

		3.1.1	pay $10.00 to each of the Assignors and issue to the University one million, two hundred and fifty thousand
(1,250,000) Founder shares at a deemed price of $0.00001 per share; and

 

		3.1.2	enter into a Research Agreement with the University to fund further research to be conducted by or under
the supervision of Cashman to develop the Invention further.

 

		3.2	The University acknowledges that the shares it receives under clause 3.1.1 above are in full and final
payment of its Revenue Interest related to the assignment of the Invention hereunder and no further compensation
or other amounts shall be due from the Company or the Inventors to the University with respect to this assignment or the Company's use
of the Invention.

 

    2

     

    

 

		3.3	All transfers of shares shall be permanent and non-refundable.

 

		4.	LICENSE TO USE

 

		4.1	The Assignee acknowledges that the University has reserved a non-assignable, non-sublicensable, non-transferable,
perpetual, royalty free, non-exclusive license to use the Invention for research, teaching and administrative purposes.

 

		4.2	The Assignee acknowledges that the Assignors reserve a non-assignable, non-sublicensable, non-transferable,
perpetual, royalty free, non-exclusive license to use the Invention for research, teaching and administrative purposes.

 

		5.	TERM AND TERMINATION

 

		5.1	The term of this Agreement shall be for the life of any patents directly related to the Invention, unless
otherwise terminated in accordance with the provisions herein.

 

		5.2	An Assignor or the University may terminate this Agreement upon 30 days written notice to Assignee if
Assignee is in breach of any of its obligations hereunder, and if Assignee has not resolved its breach to the satisfaction of the Assignor
or University within the 60 days termination period.

 

		5.3	An Assignor or the University may terminate this Agreement upon sixty (60) days written notice to Assignee
until such time that the Assignee has been successful in achieving the following milestones:

 

		5.3.1	a minimum of $1.2 million gross proceeds in financing to be raised by the Assignee or its successor or
affiliate, of which at least 75% will be committed by the Assignee or its successor or affiliate to the further development of the Invention
by June 30, 2005; and

 

		5.3.2	a minimum of $200,000 committed by the Assignee or its successor or affiliate under a Research Agreement
by April 30, 2005.

 

		5.4	This Agreement and the rights granted hereunder shall terminate immediately and revert to Assignor in
the event of any adjudication of bankruptcy, appointment of receiver by a Court of competent jurisdiction, assignment for the benefit
of creditors, involving Assignee either voluntary or involuntary, or appointment of a receiver by Assignee for any reason whatsoever.
Such termination shall not impair or prejudice any other right or remedy that Assignor may otherwise have under this Agreement.

 

		5.5	In the event of termination under 5.2, 5.3 or 5.4 all rights, title, interest and obligations granted
herein shall revert to the Assignors and the Assignee will execute an assignment to the Assignors of all the patents granted for the Invention
including any Improvements created by the Assignee then in its possession or control, if any, and the Assignee shall refrain from further
use of such Invention.

 

    3

     

    

 

		6.	DISPUTE RESOLUTION

 

		6.1	The Parties shall use their best efforts to settle in a fair and reasonable manner any disputes arising
in connection with this Agreement. Any matter that cannot be settled by the Parties between themselves shall be first submitted to a mediator
chosen jointly by the Parties. In the event that mediation does not bring a resolution satisfactory to each Party within 30 days, the
matter shall be submitted to arbitration before a single arbitrator pursuant to the Arbitration Act of Ontario.

 

		7.	LIABILITY

 

		7.1	Assignee shall at all times during the term of this Agreement and thereafter, indemnify, defend and hold
Assignors, their successors and assigns, harmless against all claims, proceedings, demands and liabilities of any kind whatsoever, including
legal expenses and reasonable attorneys' fees, arising out of the death of or injury to any person or persons or out of any damage to
property, resulting from use of the Invention for any purpose, or arising from any right or obligation of Assignee hereunder.

 

		7.2	Except as otherwise expressly set forth in this agreement, Assignors, for themselves and their successors
and assigns, make no representations and extend no warranties of any kind, either express or implied, including but not limited to warranties
of merchantability, fitness for a particular purpose, validity of rights and interests claims, issued or pending, and the absence of latent
or other defects, whether or not discoverable. Nothing in this agreement shall be construed as a representation made or warranty given
by Assignors that the practice by Assignee of the rights granted hereunder shall not infringe the rights and interests of any third party.
In no event shall Assignors, their successors or assigns, be liable for incidental or consequential damages of any kind, including economic
damage or injury to property and lost profits, regardless of whether Assignors shall be advised, shall have other reason to know, or in
fact shall know of the possibility.

 

IN WITNESS WHEREOF the Parties have caused
this Agreement to be signed by their duly authorized officers as of the day and date first above written.

 

	SIGNED in the presence of:	 	 
	 	 	 
	/s/ Marty Lehto	 	/s/ Neil R. Cashman
	Name of Witness: Marty Lehto	 	NEIL R. CASHMAN
	 	 	 
	SIGNED in the presence of:	 	 
	 	 	 
	/s/ Neil Cashman	 	/s/ Marty Lehto
	Name of Witness: Neil Cashman	 	MARTY LEHTO

 

    4

     

    

 

	THE GOVERNING COUNCIL
    OF THE UNIVERSITY OF TORONTO	 	AMORFIX LIFE SCIENCES
    LTD
	 	 	 	 	 
	By:	/s/ Peter B. Munsche	 	By:	/s/ David Raffa
	 	 	 	 	David
    Raffa
	 	Peter
    B. Munsche	 	 	VP
    Consumer Finance
	 	Assistant
    Vice-President	 	 	 
	 	Technology
    Transfer	 	 	 
	 	University
    of Tortono	 	 	 

 

    5

     

    

 

SCHEDULE "A"

 

Patent Description

 

[Intentionally omitted]

 

SCHEDULE "B"

 

Confidential
Invention Disclosure

 

[Intentionally omitted]

 

SCHEDULE "C"

 

Assignment of
Rights to the University of Toronto by Inventor

 

[Intentionally omitted]

 

SCHEDULE "D"

 

Assignment of
Rights from the University of Toronto

 

[Intentionally omitted]

 

SCHEDULE "E"

 

Amendment to
University of Toronto Confidential Invention Disclosure and Related Assignment

 

[Intentionally omitted]Exhibit 10.35.1

 

 This Amending Agreement is made
the 1st day of April, 2005 between

 

NEIL R. CASHMAN ("Cashman"),
MARTY LEHTO ("Lehto") (together the "Assignors"), THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO ("University")
and AMORFIX LIFE SCIENCES LTD (the "Assignee") (collectively the "Parties").

 

The Parties entered into an assignment agreement
dated the 18th day of February, 2005 under which the Assignors with the permission of the University assigned and transferred
all rights, title and interest in their epitope protection technology to the Assignee (the "Assignment Agreement"); and

 

As partial consideration for the assignment of
rights the Assignee was required to fund further research at the University to develop the invention further under the supervision of
Cashman; and

 

If Assignee did not enter into a research agreement
with the University for at least $200,000.00 in research funding by April 30, 2005 the University or the Assignors could revoke the assignment
upon 60 days written notice; and

 

The imminent departure of Cashman from the University
has made those conditions impossible to achieve and thus the Parties now wish to amend the Assignment Agreement by reference herein; thus

 

The Parties hereby agree as follows:

 

		1.	Except as otherwise defined herein, any capitalized terms used in this Amending Agreement shall have the
meanings prescribed by the Assignment Agreement.

 

		2.	Article 3.1.2 of the Assignment Agreement is deleted and replaced by the following:

 

		3.1.2	fund further research to be conducted by or under the supervision of Cashman to develop the Invention
further;

 

		3.	The milestones in Article 5.3 of the Assignment Agreement are deleted and replaced by the following:

 

		5.3.1	a minimum of $1.2 million gross proceeds in financing to be raised by the Assignee or its successor or
affiliate

 

		5.3.2	a minimum of $200,000.00 spent by the Assignee or its successor or assignee on the further research and
development of the Invention.

 

		4.	The Assignee agrees to indemnify and hold harmless the University and the Assignors for any and all loss
or damages suffered by the Assignee with respect to further research and development of the Invention and the Assignee further releases
and relieves the University and the Assignors of all liabilities, duties and obligations, incurring as a result of the Assignee's inability
to undertake further research and development of the Invention at the University.

 

    1

     

    

 

		5.	All other terms of the Assignment Agreement remain unchanged and in full force and effect.

 

IN WITNESS WHEREOF the Parties have caused this
Agreement to be signed by their duly authorized officers as of the day and date first above written.

 

	SIGNED
    in the presence of:	 	 
	 	 	 
	/s/
    Vigen Nazarian	 	/s/
    Neil R. Cashman
	Name of Witness:
    Vigen Nazarian	 	NEIL
    R. CASHMAN
	 	 	 
	SIGNED
    in the presence of:	 	 
	 	 	 
	s/
    Vigen Nazarian	 	/s/
    Marty Lehto
	Name of Witness:
    Vigen Nazarian	 	MARTY
    LEHTO

 

	THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO	 	AMORFIX LIFE SCIENCES
    LTD
	 	 	 	 	 
	By:	/s/ Peter B.
    Munsche	 	By:	/s/ George Adams
	 	 	 	 	George Adams
	 	Peter B. Munsche	 	 	 
	 	Assistant Vice-President	 	 	 
	 	Technology Transfer	 	 	 
	 	University of Toronto	 	 	 

 

    2

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00345-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00345-of-00352.parquet"}]]